Search Results for "President CEO Epicentre Biotechnologies"

20:31 EDT 26th May 2017 | BioPortfolio

Matching Channels

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Matching News

Lucigen to Distribute Entire Epicentre Product Line

Lucigen Corporation announces it has signed a global agreement with Illumina, Inc. for Lucigen to be the sole distributor of Epicentre Technologies’ genomics kits, enzymes and a...

Lucigen Corporation To Distribute Entire Epicentre Product Line

  Life Sciences Jobs   ...

Mount Tam Biotechnologies, Inc., to present at Bio CEO Investor Conference

NOVATO, CA--(Marketwired - Feb 9, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") ( OTC PINK : MNTM), a company focused on the Read more...

Elanix Biotechnologies: Erfolgreiche Finanzierungsrunde

Elanix Biotechnologies hat eine Kapitalerhöhung erfolgreich abgeschlossen. Insgesamt werden 1,133 Millionen Aktien ausgegeben. Der Bezugspreis je Aktie liegt bei 4,20 Euro. Somit kommen brutto 4,76.....

Ethrog Biotechnologies iBlot Invitrogen Dry Blotter Gel Transfer System

C $158.17End Date: Monday Apr-10-2017 12:36:52 EDTBuy It Now for only: C $158.17Buy It Now | Add to watch list Biotech365 : Ethrog Biotechnologies iBlot Invitrogen Dry Blotter Gel Transfer System...

Lion Biotechnologies to Present at Upcoming Investor Conferences in March

SAN CARLOS, CA--(Marketwired - February 27, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (...

Lion Biotechnologies Harnesses TIL Technology to Attack Cancers

ArticleImmunotherapy is one of the biggest things in oncology at the moment and San Francisco-based Lion Biotechnologies Inc., is pushing ahead using tumor-infiltrating lymphocytes (TIL) to destroy so...

Adaptive Biotechnologies, Amgen partner to develop sequencing-based ALL assay

Adaptive Biotechnologies has partnered with biopharmaceutical firm Amgen to advance the development of clonoSEQ assay in acute lymphoblastic leukemia (ALL).

Matching PubMed Articles

President's Editorial -A President's Insight into the AAFS.

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.

Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was t...

Maintaining US Leadership in Emerging Biotechnologies to Grow the Economy of the Future.

Pence, Putin, Mbeki and Their HIV/AIDS-Related Crimes Against Humanity: Call for Social Justice and Behavioral Science Advocacy.

Indiana, a large rural state in the Midwestern United States, suffered the worst North American HIV outbreak among injection drug users in years. The Indiana state government under former Governor and...

Better together: Collaborative family healthcare association and the promise of team-based care.

In this presidential column is a personal introduction of the new president of the Collaborative Family Healthcare Association (CFHA), Christine Runyan. As president she hopes to continue to support t...

Search Whole site using Google

Quick Search
Advertisement Advertisement